Deciphera Prelim Phase 1b/2 Combo Endometrial Cancer Data at ASCO

Combination of Rebastinib and Paclitaxel Demonstrates Encouraging Anti-tumor Activity and Favorable Tolerability in Patients with Advanced Endometrial Cancer

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the presentation of data from the endometrial cancer cohort of Part 2 of its ongoing Phase 1b/2 clinical trial of rebastinib, the Company’s investigational orally administered, potent and selective inhibitor of the TIE-2 kinase, in combination with paclitaxel. The presentation, titled “An open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel in a dose expansion cohort to assess safety and preliminary efficacy in patients with advanced or metastatic endometrial cancer” (abstract 6085; poster 256), will be featured during a poster session at the American Society of Clinical Oncology (ASCO) 2020 Virtual Scientific Program.
“We are very encouraged by the preliminary data from the endometrial cancer cohort,” said Matthew L. Sherman, M.D., Executive Vice President and Chief Medical Officer of Deciphera. “Of the 18 patients included in the modified intent-to-treat population, there were seven partial responses observed, four of which were confirmed, and six patients had stable disease, for an objective response rate of 39% and a clinical benefit rate of 72% at eight weeks. These findings continue to support the potential of TIE-2 inhibition with rebastinib in combination with paclitaxel, including in patients with prior exposure to paclitaxel.”

https://www.marketscreener.com/DECIPHERA-PHARMACEUTICALS-37892977/news/Deciphera-Pharmaceuticals-Presents-Preliminary-Data-from-Phase-1b-2-Study-of-Rebastinib-in-Combina-30693005/